Drug Trial Radar · NCT07951463
A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
375
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Apr 30, 2029
Study completion Aug 31, 2030
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.
Conditions
- Non-small Cell Lung Cancer
Interventions
Glumetinib TabletsDrug
Glumetinib 300 mg QD orally under fasting conditions
PlaceboDrug
Placebo 300 mg QD orally under fasting conditions
Osimertinib Mesylate TabletsDrug
Administered orally at a dose of 80 mg QD orally
Pemetrexed/CarboplatinDrug
Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Pemetrexed/CisplatinDrug
Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- FS as assessed by IRCTime frame: Up to approximately 42 months after the first patient is enrolled
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.